PRF Technologies Ltd. PRFX
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-7.47
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.0K | $0 | $0 | — | — | — | — | — | — |
| Cost of revenue | $70.0K | $0 | $0 | — | — | — | — | — | — |
| Gross profit | -$53.0K | $0 | $0 | — | — | — | — | — | — |
| R&D | $1.1M | $11.7M | $6.0M | $4.4M | $2.9M | $354.0K | $136.0K | $223.0K | — |
| SG&A | $1.4M | $1.3M | $1.7M | $2.1M | $2.2M | $1.3M | $553.0K | $277.0K | — |
| Operating income | -$5.1M | -$14.7M | -$9.6M | -$8.9M | -$7.2M | -$1.7M | -$689.0K | -$500.0K | — |
| Interest expense | — | — | — | $0 | $0 | $987.0K | — | — | — |
| Pre-tax income | -$5.0M | -$14.6M | -$9.3M | -$8.8M | -$7.2M | -$3.8M | -$1.3M | -$828.0K | — |
| Income tax | $8.0K | $8.0K | $8.0K | $9.0K | $6.0K | $220.0K | $0 | — | — |
| Net income | -$5.0M | -$14.6M | -$9.3M | -$8.8M | -$7.2M | -$4.1M | -$1.3M | -$828.0K | — |
| EPS, basic | -7.47 | -105.52 | -122.94 | -63.46 | -7.25 | -1.25 | — | — | — |
| EPS, diluted | -7.47 | -105.52 | -122.94 | -63.46 | -7.25 | -1.25 | -4.17 | -3.24 | — |
| Shares, diluted (wtd. avg.) | 647,973 | 138,254 | 76,005 | 138,548 | 999,562 | 3.2M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.1M | $4.3M | $8.0M | $4.1M | $16.6M | $15.7M | $947.0K | $46.0K | $193.0K |
| Short-term investments | — | — | $0 | $6.1M | $0 | — | — | — | — |
| Total current assets | $4.4M | $4.4M | $9.8M | $12.3M | $19.0M | $17.8M | $972.0K | — | — |
| Property, plant and equipment | $30.0K | $35.0K | $38.0K | $44.0K | $53.0K | $10.0K | — | — | — |
| Goodwill | $186.0K | $0 | — | — | — | — | — | — | — |
| Other intangibles | $7.4M | $0 | — | — | — | — | — | — | — |
| Total assets | $12.0M | $4.5M | $9.9M | $12.3M | $19.1M | $17.8M | $1.2M | — | — |
| Total current liabilities | $2.4M | $2.4M | $2.4M | $1.1M | $757.0K | $961.0K | $6.3M | — | — |
| Total liabilities | $2.7M | $2.7M | $2.7M | $1.3M | $991.0K | $1.2M | — | — | — |
| Retained earnings | -$61.3M | -$56.5M | -$41.9M | -$32.5M | -$23.7M | -$16.5M | -$12.4M | — | — |
| Total equity | $8.5M | $1.8M | $7.2M | $11.0M | $18.1M | $16.6M | -$12.2M | -$11.1M | -$10.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.0M | -$12.6M | -$6.7M | -$6.5M | -$6.6M | -$2.6M | -$609.0K | -$635.0K | — |
| Depreciation and amortisation | $15.0K | $16.0K | $15.0K | $15.0K | $7.0K | — | $1.0K | — | — |
| Stock-based compensation | $447.0K | $310.0K | $804.0K | $1.4M | $812.0K | $38.0K | $89.0K | — | — |
| Capital expenditure | $2.0K | $13.0K | $9.0K | $6.0K | $50.0K | $10.0K | $0 | — | — |
| Investing cash flow | -$982.0K | -$13.0K | $6.0M | -$6.0M | -$50.0K | -$10.0K | $0 | — | — |
| Financing cash flow | $3.8M | $8.9M | $4.6M | $0 | $7.5M | $17.3M | $1.5M | $488.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001178913-26-001782.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 | $17.0K |
| Gross profit | — | — | — | — | — | — | $0 | $0 | -$53.0K |
| Net income | — | -$828.0K | -$1.3M | -$4.1M | -$7.2M | -$8.8M | -$9.3M | -$14.6M | -$5.0M |
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |